| Nov 13 |
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
|
| Nov 4 |
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
|
| Oct 28 |
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
|
| Oct 21 |
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
|
| Oct 10 |
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
|
| Oct 9 |
ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...
|
| Oct 2 |
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
|
| Sep 9 |
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
|
| Aug 26 |
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
|
| Aug 26 |
ImmunoPrecise Antibodies receives non-compliance notice from Nasdaq
|
